Management of gestational trophoblastic disease: results of a cooperative study.
Three hundred fifty-four evaluable cases of hydatidiform mole diagnosed from 1970 to 1979 in 10 regional hospitals in Lombardy are analyzed in the present report. Twenty-six (7.3%) of the patients developed persistent trophoblastic disease. Younger (less than 20 years) and older (40 years or more) age at diagnosis, a large-for-dates uterus, and ovarian enlargement were associated with an increased risk of developing persistent trophoblastic disease. Twenty-three (9%) cases of persistent trophoblastic disease were observed among 250 women not prophylactically treated, but only in 3 (3%) among 104 who received prophylactic chemotherapy. High-risk groups are defined and the role of prophylactic chemotherapy is discussed.
D000293:Adolescent; D000328:Adult; D006063:Chorionic Gonadotropin / Q000097:blood; D004107:Dilatation and Curettage; D015237:Dinoprost; D005260:Female; D006801:Humans; D007373:Interinstitutional Relations; D007558:Italy; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D009775:Obstetrics and Gynecology Department, Hospital; D010053:Ovary / Q000473:pathology; D011247:Pregnancy; D011460:Prostaglandins F / Q000627:therapeutic use; D014328:Trophoblastic Neoplasms / Q000453:epidemiology / Q000517:prevention & control / Q000628:therapy*; D014594:Uterine Neoplasms / Q000453:epidemiology / Q000517:prevention & control / Q000628:therapy*
D006063:Chorionic Gonadotropin; D011460:Prostaglandins F; D015237:Dinoprost; D008727:Methotrexate